Geroprotective effects of Alzheimer's disease drug candidates

Area of Science:

• Gerontology and aging research
• Neuroscience and neurodegenerative diseases
• Nephrology and kidney disease

Background:

• Geroprotectors are compounds that slow biological aging, potentially extending healthy lifespan by maintaining youthful organ function.
• This hypothesis is largely untested in mammals, particularly regarding brain and kidney health.
• Alzheimer's disease drug candidates J147 and CMS121 have shown life-extending properties in model organisms.

Purpose of the Study:

• To investigate if J147 and CMS121, known geroprotectors in invertebrates, preserve youthful function in the brain and kidney of aging mice.
• To determine if these compounds can counteract age-associated protein alterations in these organs.
• To explore the tissue-specific mechanisms of action for these geroprotective compounds.

Main Methods:

• Utilized senescence-accelerated SAMP8 mice, a model for rapid aging.
• Administered J147 and CMS121 during the last quadrant of the mice's lifespan.
• Analyzed age-associated protein level alterations in brain and kidney tissues.
• Assessed physiological markers for brain and kidney function.

Main Results:

• Both J147 and CMS121 improved physiological markers for brain and kidney function in aging mice.
• Distinct, tissue-specific protein level alterations were observed with aging in the brain and kidney.
• Drug treatments successfully restored protein levels to a more youthful state in both organs.
• The compounds demonstrated efficacy in preventing age-associated disease markers in both brain and kidney.

Conclusions:

• Geroprotective Alzheimer's disease drug candidates J147 and CMS121 prevent age-associated disease in both brain and kidney.
• These compounds maintain youthful protein levels in aging organs.
• The mode of action for J147 and CMS121 is distinct in the brain and kidney, highlighting tissue-specific effects.